BioCentury
ARTICLE | Clinical News

Feraheme regulatory update

September 10, 2012 7:00 AM UTC

AMAG said Swissmedic approved Rienso ferumoxytol to treat iron deficiency anemia in chronic kidney disease (CKD) patients. The IV iron replacement therapy is approved for the indication in the U.S. and Canada as Feraheme, and in the EU as Rienso. AMAG markets Feraheme in the U.S. and said partner Takeda plans to launch the product in Canada and the EU this half. ...